

Van: [CCMO - Bevoegde Instantie / Competent Authority](#)
Aan: [ccmo_frontoffice](#)
Onderwerp: FW: NL67478.078.18 Submission of Clinical Study Report
Datum: dinsdag 22 maart 2022 11:13:08
Bijlagen: [CSR submission CA GLPG 1690-CL-304.zip](#)

Studierapport voor Marjolein.

Groet, 5.1.2.e

Van: 5.1.2.e <5.1.2.e@ppd.com>
Verzonden: maandag 21 maart 2022 17:03
Aan: CCMO - Bevoegde Instantie / Competent Authority <bi@ccmo.nl>
Onderwerp: NL67478.078.18 Submission of Clinical Study Report

Concerns: Submission of Clinical Study Report Synopsis
Protocol number: GLPG1690CL304
EudraCT number: 2018-001406-29
NL number: NL67478.078.18

Dear members of the Central Committee on Research Involving Human Subjects,

On behalf of our client, Galapagos NV (GLPG), please find enclosed the clinical study report synopsis for the study dd 18-Oct-2021: for the study entitled "A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis", registered under NL67478.078.1823.

Please find the documents supporting this application attached.

We would appreciate a confirmation of receipt and hope to have informed you sufficiently this way.

Should you have any questions regarding this submission, please do not hesitate to contact us.

Yours sincerely,

5.1.2.e

5.1.2.e

On behalf of

PPD, Part of Thermo Fisher Scientific

HB Switzerland

Regional Operational Delivery - Germany, Austria, Switzerland, The Netherlands
Clinical Operations

Cell +41 5.1.2.e

5.1.2.e [@ppd.com](#)

www.ppd.com

Early Development | Clinical Development | Laboratories | Post-Approval | Consulting

PPD Germany GmbH & Co. KG Sulzbacher Str. 48 90489 Nuernberg
Geschaeftsfuehrer: 5.1.2.e - Sitz: Nuernberg,
Registergericht Nuernberg HRA 11164 - Mannheim HRB 107607
Komplementaer: PPD Germany GmbH - Kommanditist: PPD International Holdings
GmbH
UST(VAT)-ID: DE185495394 - Steuer-Nr. 238/172/63607

This email transmission and any documents, files or previous email messages attached to it may contain information that is confidential or legally privileged. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of this transmission is strictly prohibited. If you have received this transmission in error, please immediately notify the sender by telephone or return email and delete the original transmission and its attachments without reading or saving in any manner.